Scientific Program

Print
Hall A


Exhibition Hall – Thursday 5th November, 2015
 
18:00-18:45
Welcome Reception
Hall A - Thursday 5th November, 2015
Plenary Session 1 18:45-19:45 Special Opening Ceremony
18:45-18:50 Chairpersons: I. Raz, Israel and H. Ilkova, Turkey
  18:50-18:30
The cardiovascular outcome trial – where are we?
S. Del Prato, Italy
  18:30-18:35 Discussion


Hall A - Friday 6th November, 2015
 
Plenary Session
08:00-09:00
Novel Therapy in the Treatment of Type 2 Diabetes
  08:00-08:10
Chairpersons: I. Raz, Israel, W.T. Cefalu, USA, H. Ilkova, Turkey and S. Del Prato, Italy
  08:10-08:30
The present and future
R.A. DeFronzo, USA
 
08:30-08:50
Personalized theraoy by genotype
V. Lyssenko, Sweden
  08:50-09:00
Discussion and Program Overview
 
Session 2
09:00-10:30
Hot Questions in Diabetes
  09:00-09:05 Chairpersons: O. Deyneli, Turkey and G. Schernthaner, Austria

 
 
 
 
09:05-09:20
09:20-09:35
09:35-09:45
Initial use of combination therapy
Yes: A. Cahn, Israel
No: W.T. Cefalu, USA
Discussion

 
 
 
 
09:45-10:00
10:00-10:15
10:15-10:30
Hypoglycemia and CV risk, is there a major link?
Yes: N. Shehadeh, Israel
No: M. Hanefeld, Germany
Discussion
10:30-11:00
Coffee Break
 
Session 5
11:00-12:30
Novel Insulin Analogues
  11:00-11:05 Chairpersons: T. Yilmaz, Turkey and B. Charbonnel, France
 
 
 
 
 
11:05-11:20
11:20-11:35
11:35-11:45
Ultra long acting basal insulin – does benefit outweigh cost?
Yes: G. Bolli, Italy
No: E. Standl, Germany
Discussion
 
 
 
 
 
11:45-12:00
12:00-12:15
12:15-12:30
Biosimilar in insulin therapy
Yes: P. Pozzilli, Italy
No: G. Bolli, Italy
Discussion
12:30-12:40
Lunchbox Pick Up
12:40-13:50
Industrial Satellite Symposium
 
13:50-14:10
Coffee & Dessert
 
Session 8
14:10-15:40
What Next After Metformin?
 
14:10-14:15
Chairpersons: S. Akalin, Turkey G. Bolli, Italy

14:15-14:40
According to ADA/EASD position of PPRG- neutral standing
M.A. Nauck, Germany

14:40-15:05
According to AACE guidelines - prioritize by individual benefits of medication
B. Hoogwerf, USA

15:05-15:30
According to Israeli guidelines - prioritize by individualized patient characteristics
O. Mosenzon, Israel
  15:30-15:40 Discussion
Session 11
15:40-17:10
SGLT-2 Inhibitors
15:40-15:45 Chairpersons: A. Çömlekçi, Turkey and B. Itzhak, Israel
 
15:45-16:10
Positioning SGLT-2 inhibitors in teh treatment algorithm
J. Wilding, UK

16:10-16:35
 
Incretin/SGLT2 alone and in combination – treatment algorithm
R.A. DeFronzo, USA

16:35-17:00
SGLT2 inhibitors and the diabetic kidney
P. Fioretto, Italy
  17:00-17:10 Discussion
 

17:10-17:30
Coffee Break

17:30-19:00
Industrial Satellite Symposium

Hall A - Saturday 7th November, 2015
 
Session 14
08:00-09:30
Choice of Therapy I
 
08:00-08:05
Chairpersons: S. Gündoğdu, Turkey and P. Home, UK
 
 
08:05-08:20
08:20-08:35
08:35-08:45
Do sulfonylureas still have a role in diabetes treatment?
Yes: J. Davidson, USA
No: S. Parikh, USA
Discussion

 
08:45-09:00
09:00-09:15
09:15-09:30
Crossroad for critical decisions
GLP-1: O. Mosenzon, Israel
Insulin: P. Home, UK
Discussion

09:30-10:00
Coffee Break

Session 16
10:00-11:30
Choice of Therapy II
10:00-10:05
Chairpersons: O. Deyneli, Turkey and J. Davidson, USA
 
 
10:05-10:20
10:20-10:35
10:35-10:45
Prandial insulin vs. GLP1
Insulin: E. Standl, Germany
GLP1: J. Davidson, USA
Discussion

 
10:45-11:00
11:00-11:15
11:15-11:30
Should we individualize GLP-1 treatment?
Yes: Mariela Glandt, Israel
No: I. Raz, Israel
Discussion
 
Session 18
11:30-13:00
Controversies Regarding Diabetes and Cancer
11:30-11:35
Chairpersons: R. Serter, Turkey and P. Pozzilli, Italy

11:35-12:05
Obesity, diabetes and cancer: New insight into the pathophysiology:
M.A. Nauck, Germany

12:05-12:35
 
Do antihyperglycemic drugs affect cancer risk and mortality?
M.A. Nauck, Germany
  12:35-13:00 Discussion
 
13:00-13:10
Lunchbox Pickup
 
13:10-14:10
Industrial Satellite Symposium
 
14:10-14:30
Coffee & Dessert
 
 
Session 20
14:30-16:00
Preventing Diabetes
14:30-14:35
Chairperson: I. Yetkin, Turkey and I. Raz, Switzerland

 
14:35-14:50
14:50-15:05
15:05-15:15
Early vs. Late
Very early pre diabetes: J. Tuomilehto, Finland
Very late pre diabetes: J. Tuomilehto, Finland
Discussion

 
15:15-15:30
15:30-15:45
15:45-16:00
Can we slow diabetes progression?
Yes: R.A. Defronzo, USA
No: J. Tuomilehto, Finland
Discussion
 
Plenary Session 22
16:00-17:00
Resistant Hypertension
16:00-16:05 
Chairperson: S. Erdine, Turkey and Peter Nilsson, Sweden
16:05-16:20
How common is true resistant hypertension? A. Solini, Italy

 
 
16:20-16:35
16:35-16:50
16:50-17:00
Renal artery stenosis - To intervene or not?
Yes: P. Sarafidis, Greece
No: P. Nilsson, Sweden
Discussion
 

17:00-18:00
Guided Poster Tours and Refreshments